Table 4.
Results of Univariate Analysis for Overall Survival
| Covariate | Median Score | Median Survival Time (months) | 5-Year Overall Survival |
Hazard Ratio | 95% CI | χ2P | |
|---|---|---|---|---|---|---|---|
| % | 95% CI | ||||||
| EORTC QLQ-C30: global QOL score (n = 217) | < 66.7 | 15.4 | 11 | 6 to 17 | 1.69 | 1.23 to 2.33 | .001† |
| ≥ 66.7* | 27.1 | 27 | 17 to 38 | ||||
| EORTC LC-13: dyspnea score (n = 210‡) | < 22.2* | 20.8 | 19 | 10 to 29 | 1.37 | 1.01 to 1.86 | .046 |
| ≥ 22.2 | 15.6 | 15 | 9 to 22 | ||||
| EORTC QLQ-C30: physical functioning (n = 216§) | < 86.7 | 16.2 | 12 | 7 to 19 | 1.29 | 0.95 to 1.75 | .098 |
| ≥ 86.7* | 18.8 | 23 | 14 to 34 | ||||
| KPS (n = 217) | 70-80 | 14.1 | 14 | 6 to 25 | 1.47 | 1.05 to 2.08 | .026‖ |
| 90-100* | 19.8 | 17 | 12 to 24 | ||||
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; QLQ, Quality of Life Questionnaire; QOL, quality of life; LC-13, Lung Cancer 13; KPS, Karnofsky performance score.
*
Reference level: better functioning/less symptom severity.
†
Statistically significant using α = .01.
‡
Seven patients did not answer this question.
§
One patient did not answer this question.
‖
Statistically significant using α = .05.